Skip to main content

Pluvicto Dosage

Generic name: LUTETIUM LU-177 VIPIVOTIDE TETRAXETAN 27mCi in 1mL
Dosage form: injection, solution
Drug class: Therapeutic radiopharmaceuticals

Medically reviewed by Drugs.com. Last updated on Sep 11, 2024.

2.1 Important Safety Instructions

PLUVICTO is a radiopharmaceutical; handle with appropriate safety measures to minimize radiation exposure. Use waterproof gloves and effective radiation shielding when handling PLUVICTO.

Radiopharmaceuticals, including PLUVICTO, should be used by or under the control of healthcare providers who are qualified by specific training and experience in the safe use and handling of radiopharmaceuticals, and whose experience and training have been approved by the appropriate governmental agency authorized to license the use of radiopharmaceuticals.

2.2 Patient Selection

Select patients with previously treated mCRPC for treatment with PLUVICTO using LOCAMETZ or another approved PSMA-11 imaging agent based on PSMA expression in tumors. Additional selection criteria were used in the VISION study.

Refer to the prescribing information for the PSMA imaging agent.

2.3 Recommended Dosage

The recommended PLUVICTO dosage is 7.4 GBq (200 mCi) intravenously every 6 weeks for up to 6 doses, or until disease progression, or unacceptable toxicity.

2.4 Dosage Modifications for Adverse Reactions

Recommended dosage modifications of PLUVICTO for adverse reactions are provided in Table 1. Management of adverse reactions may require temporary dose interruption (extending the dosing interval from every 6 weeks up to every 10 weeks), dose reduction or permanent discontinuation of treatment with PLUVICTO. If a treatment delay due to an adverse reaction persists for > 4 weeks, treatment with PLUVICTO must be discontinued. The dose of PLUVICTO may be reduced by 20% to 5.9 GBq (160 mCi) once; do not re-escalate dose. If a patient has further adverse reactions that would require an additional dose reduction, treatment with PLUVICTO must be discontinued.

Table 1: Recommended Dosage Modifications of PLUVICTO for Adverse Reactions
Abbreviations: CLcr, creatinine clearance; AST, aspartate aminotransferase; ALT, alanine aminotransferase; ULN, upper limit of normal.
Grading according to most current Common Terminology Criteria for Adverse Events (CTCAE).
Adverse reaction Severity Dosage modification
Myelosuppression
(Anemia, thrombocytopenia, leukopenia, or neutropenia)
 Grade 2 Withhold PLUVICTO until improvement to Grade 1 or baseline.
Grade ≥ 3 Withhold PLUVICTO until improvement to Grade 1 or baseline.
Reduce PLUVICTO dose by 20% to 5.9 GBq (160 mCi).
Recurrent Grade ≥ 3 myelosuppression after one dose reduction Permanently discontinue PLUVICTO.
Renal toxicity
 Defined as:
  • Confirmed serum creatinine increase (Grade ≥ 2)
  • Confirmed CLcr < 30 mL/min; calculate using Cockcroft-Gault with actual body weight
 Withhold PLUVICTO until improvement.
Defined as:
  • Confirmed ≥ 40% increase from baseline serum creatinine
    and
  • Confirmed > 40% decrease from baseline CLcr; calculate using Cockcroft-Gault with actual body weight
 Withhold PLUVICTO until improvement or return to baseline.
Reduce PLUVICTO dose by 20% to 5.9 GBq (160 mCi).
Grade ≥ 3 renal toxicity Permanently discontinue PLUVICTO.
Recurrent renal toxicity after one dose reduction Permanently discontinue PLUVICTO.
Dry mouth Grade 2 Withhold PLUVICTO until improvement or return to baseline.
Consider reducing PLUVICTO dose by 20% to 5.9 GBq (160 mCi).
Grade 3 Withhold PLUVICTO until improvement or return to baseline.
Reduce PLUVICTO dose by 20% to 5.9 GBq (160 mCi).
Recurrent Grade 3 dry mouth after one dose reduction Permanently discontinue PLUVICTO.
Gastrointestinal toxicity Grade ≥ 3 (not amenable to medical intervention) Withhold PLUVICTO until improvement to Grade 2 or baseline.
Reduce PLUVICTO dose by 20% to 5.9 GBq (160 mCi).
Recurrent Grade ≥ 3 gastrointestinal toxicity after one dose reduction Permanently discontinue PLUVICTO.
Fatigue Grade ≥ 3 Withhold PLUVICTO until improvement to Grade 2 or baseline.
Electrolyte or metabolic abnormalities Grade ≥ 2 Withhold PLUVICTO until improvement to Grade 1 or baseline.
AST or ALT elevation AST or ALT > 5 times ULN in the absence of liver metastases Permanently discontinue PLUVICTO.
Other non-hematologic toxicity Any unacceptable toxicity Permanently discontinue PLUVICTO.
Any serious adverse reaction that requires treatment delay of > 4 weeks Permanently discontinue PLUVICTO.
Any recurrent Grade 3 or 4 or persistent and intolerable Grade 2 adverse reaction after one dose reduction Permanently discontinue PLUVICTO.

2.5 Preparation and Administration

Preparation Instructions

  • Use aseptic technique and radiation shielding when handling or administering PLUVICTO, using tongs as needed to minimize radiation exposure.
  • Inspect the vial visually under a shielded screen for particulate matter and discoloration prior to administration. Discard the vial if particulates or discoloration are present.
  • Do not inject the PLUVICTO solution directly into any other intravenous solution.
  • Confirm the amount of radioactivity delivered to the patient with an appropriately calibrated dose calibrator prior to and after PLUVICTO administration.
  • Dispose of any unused medicinal product or waste material in accordance with local and federal laws.

Administration Instructions

The recommended dosage of PLUVICTO may be administered intravenously as an injection using a disposable syringe fitted with a syringe shield (with or without a syringe pump), as an infusion using the gravity method (with or without an infusion pump), or as an infusion using the vial (with a peristaltic infusion pump).

A reduced dose of PLUVICTO should be administered using the syringe method (with or without a syringe pump) or the vial method (with a peristaltic infusion pump). Using the gravity method to administer a reduced dose of PLUVICTO is not recommended since it may result in delivery of the incorrect volume of PLUVICTO, if the dose is not adjusted prior to administration.

Prior to administration, flush the intravenous catheter used exclusively for PLUVICTO administration with ≥ 10 mL of 0.9% sterile sodium chloride solution to ensure patency and to minimize the risk of extravasation. Manage cases of extravasation as per institutional guidelines.

Instructions for the Syringe Method (With or Without a Syringe Pump)

  • After disinfecting the vial stopper, withdraw an appropriate volume of PLUVICTO solution to deliver the desired radioactivity by using a disposable syringe fitted with a syringe shield and a disposable sterile needle.
  • Administer PLUVICTO to the patient by slow intravenous push within approximately 1 to 10 minutes (either with a syringe pump or manually without a syringe pump) via an intravenous catheter that is pre-filled with 0.9% sterile sodium chloride solution and that is used exclusively for PLUVICTO administration to the patient.
  • Once the desired PLUVICTO radioactivity has been administered, perform an intravenous flush of ≥ 10 mL of 0.9% sterile sodium chloride solution through the intravenous catheter to the patient.

Instructions for the Gravity Method (With or Without an Infusion Pump)

  • Insert a 2.5 cm, 20 gauge needle (short needle) into the PLUVICTO vial and connect via a catheter to 500 mL 0.9% sterile sodium chloride solution (used to transport the PLUVICTO solution during the infusion). Ensure that the short needle does not touch the PLUVICTO solution in the vial and do not connect the short needle directly to the patient. Do not allow the sodium chloride solution to flow into the PLUVICTO vial prior to the initiation of the PLUVICTO infusion and do not inject the PLUVICTO solution directly into the sodium chloride solution.
  • Insert a second needle that is 9 cm, 18 gauge (long needle) into the PLUVICTO vial, ensuring that the long needle touches and is secured to the bottom of the PLUVICTO vial during the entire infusion. Connect the long needle to the patient by an intravenous catheter that is pre-filled with 0.9% sterile sodium chloride solution and that is used exclusively for the PLUVICTO infusion into the patient.
  • Use a clamp or an infusion pump to regulate the flow of the sodium chloride solution via the short needle into the PLUVICTO vial (the sodium chloride solution entering the vial through the short needle will carry the PLUVICTO solution from the vial to the patient via the intravenous catheter connected to the long needle within approximately 30 minutes).
  • During the infusion, ensure that the level of solution in the PLUVICTO vial remains constant.
  • Disconnect the vial from the long needle line and clamp the saline line once the level of radioactivity is stable for at least five minutes.
  • Follow the infusion with an intravenous flush of ≥ 10 mL of 0.9% sterile sodium chloride solution through the intravenous catheter to the patient.

Instructions for the Vial Method (With a Peristaltic Infusion Pump)

  • Insert a 2.5 cm, 20 gauge needle (short venting needle) into the PLUVICTO vial. Ensure that the short needle does not touch the PLUVICTO solution in the vial and do not connect the short needle directly to the patient or to the peristaltic infusion pump.
  • Insert a second needle that is 9 cm, 18 gauge (long needle) into the PLUVICTO vial, ensuring that the long needle touches and is secured to the bottom of the PLUVICTO vial during the entire infusion. Connect the long needle and a 0.9% sterile sodium chloride solution to a 3-way stopcock valve via appropriate tubing.
  • Connect the output of the 3-way stopcock valve to tubing installed on the input side of the peristaltic infusion pump following the pump manufacturer’s instructions.
  • Pre-fill the line by opening the 3-way stopcock valve and pumping the PLUVICTO solution through the tubing until it reaches the exit of the valve.
  • Pre-fill the intravenous catheter which will be connected to the patient by opening the 3-way stopcock valve to the 0.9% sterile sodium chloride solution and pumping the 0.9% sterile sodium chloride solution until it exits the end of the catheter tubing.
  • Connect the pre-filled intravenous catheter to the patient and set the 3-way stopcock valve such that the PLUVICTO solution is in line with the peristaltic infusion pump.
  • Infuse an appropriate volume of PLUVICTO solution at approximately 25 mL/h to deliver the desired radioactivity.
  • When the desired PLUVICTO radioactivity has been delivered, stop the peristaltic infusion pump and then change the position of the 3-way stopcock valve so that the peristaltic infusion pump is in line with the 0.9% sterile sodium chloride solution. Restart the peristaltic infusion pump and infuse an intravenous flush of ≥ 10 mL of 0.9% sterile sodium chloride solution through the intravenous catheter to the patient.

2.6 Radiation Dosimetry

Dosimetry of lutetium Lu 177 vipivotide tetraxetan was collected in 29 patients in the VISION sub-study, in order to calculate whole body and organ radiation dosimetry. The mean and standard deviation (SD) of the estimated radiation absorbed doses to different organs for adult patients receiving PLUVICTO are shown in Table 2. The organs with the highest radiation absorbed doses are lacrimal glands, salivary glands, large intestine (left and right colon), kidneys, and urinary bladder wall. The maximum penetration of lutetium-177 in tissue is approximately 2 mm and the mean penetration is 0.67 mm.

Table 2: Estimated Radiation Absorbed Dose for PLUVICTO in VISION
*Estimated radiation absorbed dose for bone marrow is not included.
Absorbed dose per unit activity
(Gy/GBq)
N = 29		 Calculated absorbed dose
for 7.4 GBq
administration
(Gy)		 Calculated absorbed dose for
6 x 7.4 GBq
(44.4 GBq cumulative activity)
(Gy)
Organ* Mean SD Mean SD Mean SD
Adrenals 0.033 0.025 0.24 0.19 1.5 1.1
Brain 0.007 0.005 0.049 0.035 0.30 0.22
Esophagus 0.025 0.026 0.18 0.19 1.1 1.1
Eyes 0.022 0.024 0.16 0.18 0.99 1.1
Gallbladder wall 0.028 0.026 0.20 0.19 1.2 1.1
Heart wall 0.17 0.12 1.2 0.83 7.8 5.2
Kidneys 0.43 0.16 3.1 1.2 19 7.3
Lacrimal glands 2.1 0.47 15 3.4 92 21
Left colon 0.58 0.14 4.1 1.0 26 6.0
Liver 0.090 0.044 0.64 0.32 4.0 2.0
Lungs 0.11 0.11 0.76 0.81 4.7 4.9
Pancreas 0.027 0.026 0.19 0.19 1.2 1.1
Prostate 0.027 0.026 0.19 0.19 1.2 1.1
Rectum 0.56 0.14 4.0 1.1 25 6.2
Right colon 0.32 0.078 2.3 0.58 14 3.4
Salivary glands 0.63 0.36 4.5 2.6 28 16
Small intestine 0.071 0.031 0.50 0.23 3.1 1.4
Spleen 0.067 0.027 0.48 0.20 3.0 1.2
Stomach wall 0.025 0.026 0.18 0.19 1.1 1.1
Testes 0.023 0.025 0.16 0.18 1.0 1.1
Thymus 0.025 0.026 0.18 0.19 1.1 1.1
Thyroid 0.26 0.37 1.8 2.7 11 16
Total body 0.037 0.027 0.27 0.20 1.6 1.2
Urinary bladder wall 0.32 0.025 2.3 0.19 14 1.1

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer